BioCentury
ARTICLE | Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

Sanofi’s new trispecific technology could provide a growth platform for the pharma’s cancer franchise

November 23, 2019 2:07 AM UTC

Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron.

Sanofi (Euronext:SAN; NYSE:SNY) has been striving to expand its cancer franchise as its relationship with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) winds down...

BCIQ Target Profiles

CD28

CD38